Cas No. 139262-23-0, Semaglutide intermediate, amino acid

The Supply Chain Status in China

As of August 26, 2024, there are 149 potential suppliers manufacturing Semaglutide intermediate Fmoc-Lys HCl (CAS No. 139262-23-0), including 32 traders, 81 factories and 36 labs, among which:

- The 25th percentile has an average registered capital of 1 million CNY;

- The 50th percentile has an average registerd capital of 5 million CNY;

-  The 75th percentile has an average registered capital of 10.01 million CNY.

Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.

The Overall Synthesis Map of Semaglutide Side Chain

There are two routes that would yield Semaglutide side chain CAS No. 1662688-20-1. One is through solid-phase synthesis (lower part) while the other is not (upper part). Both routes converge into this Semaglutide side chain tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu, CAS No. 1118767-16-0. And this amino acid, Fmoc-Lys HCl, binds to tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu, and yield the final Semaglutide side chain.

The solid phase synthesis building blocks involves three moieties including Fmoc-AEEA (CAS No. 166108-71-0), Fmoc-Glu-OtBu (CAS No. 84793-07-7), and mono-tBu-stearate (CAS No. 843666-40-0). 

The other route does not involve solid phase synthesis. It starts from the C18 fatty acid (CAS No. 871-70-5), giving the mono-tBu-stearate. Then mono-tBu-stearate attaches with Glu, and AEEA-dimer. 

References